ARDSLEY, N.Y.--(BUSINESS WIRE)--
Acorda Therapeutics, Inc. (Nasdaq: ACOR )
today announced that the United States Patent and Trademark Office
(USPTO) Patent Trials and Appeal Board (PTAB) upheld all four patents
challenged via the inter partes review (IPR) process. U.S. Patent
Nos. 8,663,685 (the ‘685 patent), 8,440,703 (the ‘703 patent), 8,354,437
(the ‘437 patent) and 8,007,826 (the ‘826 patent) apply to AMPYRA®
(dalfampridine) Extended Release Tablets, 10 mg. These patents are set
to expire in 2025, 2025, 2026 and 2027, respectively.
“The court decision reflects the merits of the case we presented and the
validity and strength of our intellectual property for AMPYRA,” said Ron
Cohen, M.D., Acorda's President and CEO. “Medical innovation depends on
the recognition of valid intellectual property claims. Our in-house
legal team and external counsel presented a compelling case, and will
continue to defend the validity of our intellectual property rights for
AMPYRA.”
Acorda was advised by Gerald Flattmann, Naveen Modi, Thomas Phalen,
Michael Stamiello, Daniel Zeilberger, and Lucas Kressel of Paul Hastings
LLP.
These patents, as well as U.S. Patent No. 5,540,938 that also pertains
to AMPYRA, have also been challenged in the U.S. District Court for the
District of Delaware. The Court has completed the trial of the case, but
not yet issued its decision.
About Acorda Therapeutics
Founded in 1995, Acorda Therapeutics is a biotechnology company focused
on developing therapies that restore function and improve the lives of
people with neurological disorders.
Acorda has an industry leading pipeline of novel neurological therapies
addressing a range of disorders, including Parkinson’s disease, migraine
and multiple sclerosis. Acorda markets three FDA-approved therapies,
including AMPYRA® (dalfampridine) Extended Release Tablets,
10 mg.
For more information, please visit the Company’s website at: www.acorda.com.
Forward-Looking Statement
This press release includes forward-looking statements. All statements,
other than statements of historical facts, regarding management's
expectations, beliefs, goals, plans or prospects should be considered
forward-looking. These statements are subject to risks and uncertainties
that could cause actual results to differ materially, including: the
ability to realize the benefits anticipated from the Biotie and Civitas
transactions, among other reasons because acquired development programs
are generally subject to all the risks inherent in the drug development
process and our knowledge of the risks specifically relevant to acquired
programs generally improves over time; the ability to successfully
integrate Biotie’s operations and Civitas’ operations, respectively,
into our operations; we may need to raise additional funds to finance
our expanded operations and may not be able to do so on acceptable
terms; our ability to successfully market and sell Ampyra
(dalfampridine) Extended Release Tablets, 10 mg in the U.S.; third party
payers (including governmental agencies) may not reimburse for the use
of Ampyra or our other products at acceptable rates or at all and may
impose restrictive prior authorization requirements that limit or block
prescriptions; the risk of unfavorable results from future studies of
Ampyra or from our other research and development programs, including
CVT-301 or any other acquired or in-licensed programs; we may not be
able to complete development of, obtain regulatory approval for, or
successfully market CVT-301, any other products under development, or
the products that we will acquire when we complete the Biotie
transaction; the occurrence of adverse safety events with our products;
delays in obtaining or failure to obtain and maintain regulatory
approval of or to successfully market Fampyra outside of the U.S. and
our dependence on our collaborator Biogen in connection therewith;
competition; failure to protect our intellectual property, to defend
against the intellectual property claims of others or to obtain third
party intellectual property licenses needed for the commercialization of
our products; and failure to comply with regulatory requirements could
result in adverse action by regulatory agencies.
These and other risks are described in greater detail in our filings
with the Securities and Exchange Commission. We may not actually achieve
the goals or plans described in our forward-looking statements, and
investors should not place undue reliance on these statements.
Forward-looking statements made in this press release are made only as
of the date hereof, and we disclaim any intent or obligation to update
any forward-looking statements as a result of developments occurring
after the date of this press release.
View source version on businesswire.com: http://www.businesswire.com/news/home/20170309006322/en/
Source: Acorda Therapeutics, Inc.